Mr. Hayim Raclaw reports

ALZAI HEALTH CORP. PROVIDES UPDATE REGARDING MARKETING SERVICES AGREEMENT WITH EURO DIGITAL MEDIA

Further to Alzai Health Corp.'s news release dated Aug. 17, 2026, news release regarding its entry into a marketing services agreement dated Aug. 12, 2026, with Euro Digital Media Ltd. (address: 71-75 Shelton St., Covent Garden, London, United Kingdom, WC2H 9JQ), pursuant to which Euro Digital will provide market awareness and digital marketing services to the company, announces that the expected term of the services is four months (and not 12 months as previously disclosed), or budget exhaustion, whichever occurs first. The services are expected to commence following receipt of TSX-V approval (as defined below), and the company has agreed to pay Euro Digital a fee of $425,000 (U.S.), plus any applicable local taxes, for the services. The fee is payable in a single payment prior to the commencement of the services.

Under the terms of the services agreement, Euro Digital will provide the following services: create campaigns, ad groups, text ads and display ads, perform detailed keyword research, develop and manage remarketing campaigns, dynamically optimize keyword sets, conduct continuing bid management, optimize keyword options, co-ordinate with on-line advertisers and marketers corresponding to the company's on-line marketing objectives, place display advertisements, and create landing pages for advertising campaigns.

The company will not issue any securities to Euro Digital as compensation for its marketing services. As of the date hereof, to the company's knowledge, Euro Digital, including its principal, does not own any securities of the company and has an arm's-length relationship with the company. The services agreement is subject to the approval of the TSX Venture Exchange.

About Alzai Health Corp.

ALZAI Health is a healthcare technology company developing non-invasive, artificial intelligence-driven disease risk identification solutions using routine health care data. The company's proprietary platform is designed to identify individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. Alzai's technology has been validated on large-scale health care data sets and is designed for integration into existing health care infrastructure, including electronic medical record systems, cloud-based environments and enterprise health care platforms.

We seek Safe Harbor.